clinical trial · NCT01492686
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS)MCI-186PlaceboMCI-186 in open label phase
brief summary
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. The study is also to examine the safety of MCI-186 to the ALS patients.
started
Dec 31, 2011
primary completion
Sep 30, 2014
completion
Oct 31, 2014
last updated
Jul 21, 2026
official title
Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol